Part 15/19:
Perhaps the most provocative frontier is genetic engineering. Companies are developing CRISPR-based embryo editing, moving beyond restrictions that have long halted such efforts. While promising, these raise deep ethical issues—balancing potential cures against eugenic risks and societal inequality.
Notably, the absence of comprehensive U.S. legislation contrasts with active experimentation in the UAE and other regions, signaling a potential shift toward more permissive regimes, driven by technological and economic incentives.